Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep 16;64(11):1079-87.
doi: 10.1016/j.jacc.2014.07.937.

Innervation patterns may limit response to endovascular renal denervation

Affiliations

Innervation patterns may limit response to endovascular renal denervation

Abraham R Tzafriri et al. J Am Coll Cardiol. .

Abstract

Background: Renal denervation is a new interventional approach to treat hypertension with variable results.

Objectives: The purpose of this study was to correlate response to endovascular radiofrequency ablation of renal arteries with nerve and ganglia distributions. We examined how renal neural network anatomy affected treatment efficacy.

Methods: A multielectrode radiofrequency catheter (15 W/60 s) treated 8 renal arteries (group 1). Arteries and kidneys were harvested 7 days post-treatment. Renal norepinephrine (NEPI) levels were correlated with ablation zone geometries and neural injury. Nerve and ganglion distributions and sizes were quantified at discrete distances from the aorta and were compared with 16 control arteries (group 2).

Results: Nerve and ganglia distributions varied with distance from the aorta (p < 0.001). A total of 75% of nerves fell within a circumferential area of 9.3, 6.3, and 3.4 mm of the lumen and 0.3, 3.0, and 6.0 mm from the aorta. Efficacy (NEPI 37 ng/g) was observed in only 1 of 8 treated arteries where ablation involved all 4 quadrants, reached a depth of 9.1 mm, and affected 50% of nerves. In 7 treated arteries, NEPI levels remained at baseline values (620 to 991 ng/g), ≤20% of the nerves were affected, and the ablation areas were smaller (16.2 ± 10.9 mm(2)) and present in only 1 to 2 quadrants at maximal depths of 3.8 ± 2.7 mm.

Conclusions: Renal denervation procedures that do not account for asymmetries in renal periarterial nerve and ganglia distribution may miss targets and fall below the critical threshold for effect. This phenomenon is most acute in the ostium but holds throughout the renal artery, which requires further definition.

Keywords: aortic tortuosity; renal denervation; superior ostium.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1. Angiographic Confirmation of Electrode Positions Relative to the Ostium
Red arrows denote activated electrodes utilized for 2-electrode treatment (A) and 3-electrode treatment (B).
FIGURE 2
FIGURE 2. Histopathological Appearance of the Norepinephrine-Reducing Ostial Treatment
Treated renal artery sections (A) directly at or (C) ~3.0 mm away from the aorta with overlaid morphometry: ablation zone (black line), affected nerves (circled red), unaffected nerves (circled blue), and unaffected ganglion (circled green). Standardized comparison is facilitated by overlaying morphometric tracings from (A and C) onto nerve maps (B and D) with a defined, circular lumen (2.5 mm diameter). Orientation is uniform: top = ventral, left = cranial. In B and D, circle sizes denote the measured sizes of nerves (red = affected, blue = unaffected) and ganglia (green = unaffected). NEPI = norepinephrine; RA = renal artery; RDN = renal denervation; RF = radiofrequency.
FIGURE 3
FIGURE 3. Histopathological Appearance of Ostial Sympathetic Nerves
Magnified views of an unaffected nerve from Figure 2A (A) and an affected nerve from Figure 2C (B). Tyrosine hydroxylase immunostaining is strong and diffuse in the unaffected nerve (A) but patchy and granular in the affected nerve (B), which also exhibits hypercellularity and architectural disruption as part of the degenerative and proliferative response to treatment.
FIGURE 4
FIGURE 4. Nonefficacious Ostial Ablations
Maximal ablation zones along with nerve and ganglia positions and sizes at the same distance from the aorta (~0.3 mm) are depicted for treatments with norepinephrine levels as follows: 893 ng/g (A), 932 ng/g (B), and 620 ng/g (C). Circle sizes and other figure details as described in Figure 2.
FIGURE 5
FIGURE 5. Threshold to Biomarker Effect
Norepinephrine (NEPI) levels (diamonds) dependence on the percentage of affected nerves in affected arterial sections. A fit of Equation 1 (red line, R2 = 0.85) estimates the threshold as 50.3% affected nerves.
FIGURE 6
FIGURE 6. The Radial Distributions of Nerves and Ganglia Become More Diffuse Closer to the Ostium
Histograms of the relative abundances of nerves and ganglia are depicted at ostial distances of 0.3 (A), 3.0 (B), and 6.0 mm (C). Data from Figures 7A to 7C.
FIGURE 7
FIGURE 7. Cross-Sectional Nerve and Ganglion Distributions Vary With Distance From the Aorta
Composite polar coordinate distributions are depicted at distances from the aorta: 0.3 (A), 3.0 (B), and 6.0 mm (C). Nerve and ganglia are depicted by closed circles of varying radii based on measured sizes. Red dashes depict the location of an idealized lumen. Purple dashes depict the locus of points that are 2.5 and 5.0 mm away from the lumen. Orientation: top = ventral, left = cranial.
CENTRAL ILLUSTRATION
CENTRAL ILLUSTRATION. Threshold to Biomarker Effect
Renal norepinephrine levels exhibit a threshold dependence on the percentage of affected nerves (blue circles), namely those residing within or at the periphery of the ablation zone (black line). Far from the ablation zones, nerves (blue circles) and ganglia (green circles) are unaffected.

Comment in

References

    1. Mahfoud F, Ukena C, Schmieder RE, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128:132–140. - PubMed
    1. Kaiser L, Beister T, Wiese A, et al. Results of the ALSTER BP real-world registry on renal denervation employing the Symplicity system. Euro- Intervention. 2014;10:157–165. - PubMed
    1. Persu A, Azizi M, Burnier M, Staessen JA. Residual effect of renal denervation in patients with truly resistant hypertension. Hypertension. 2014;62:450–452. - PubMed
    1. Ott C, Mahfoud F, Schmid A, et al. Renal denervation in moderate treatment-resistant hypertension. J Am Coll Cardiol. 2013;62:1880–1886. - PubMed
    1. Esler MD, Krum H, Schlaich M, Schmieder RE, Bohm M, Sobotka PA. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126:2976–2982. - PubMed

Publication types